ION440
/ Ionis
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 02, 2025
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
(clinicaltrials.gov)
- P1/2 | N=48 | Recruiting | Sponsor: Ionis Pharmaceuticals, Inc. | Trial primary completion date: May 2026 ➔ Sep 2027
Trial primary completion date • Myelodysplastic Syndrome
October 22, 2024
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
(clinicaltrials.gov)
- P1/2 | N=48 | Recruiting | Sponsor: Ionis Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Myelodysplastic Syndrome
May 28, 2024
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Ionis Pharmaceuticals, Inc.
New P1/2 trial • Myelodysplastic Syndrome
1 to 3
Of
3
Go to page
1